|The full article is available to subscribers||Subscriber Login|
Drugs available for treatment of chronic hypertension in the US and their dosages, adverse effects, and costs are listed in the tables. Treatment of hypertensive urgencies and emergencies is not discussed here.
NEW BLOOD PRESSURE GOALS — Previously published guidelines recommend a blood pressure goal of 140/90 mm Hg for most patients with hypertension and 150/90 mm Hg for some patients ≥60 years old, but new data have recently become available.
With the publication of the Systolic Blood Pressure Intervention trial (SPRINT), the systolic blood pressure goal of <140 mm Hg may be lowered for some patients. In SPRINT, patients >50 years old with a systolic blood pressure of 130-180 mm Hg and an increased cardiovascular risk (but without diabetes or a history of stroke) were randomized to a systolic blood pressure target of <120 mm Hg (intensive treatment) or <140 mm Hg (standard treatment).... more
- SPRINT Research Group et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103.
- JD Williamson et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016; 315:2673.
- AA Leung et al. Hypertension Canada’s 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol 2016; 32:569.
- GM Gabb et al. Guideline for the diagnosis and management of hypertension in adults - 2016. Med J Aust 2016; 205:85.
- A Qaseem et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017 Jan 17 (epub).
- JT Wright Jr et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.
- GC Roush et al. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19:5.
- VM Musini et al. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015; 5:CD003825.
- DA Calhoun et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63:451.
- DA Calhoun and WB White. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462.
- Drugs for chronic heart failure. Med Lett Drugs Ther 2015; 57:9.
- Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49:29.
- F Turnbull et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527.
- K Jamerson et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417.
- WH Frishman and E Saunders. ß-adrenergic blockers. J Clin Hypertens (Greenwich) 2011; 13:649.
- CS Wiysonge et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012; 11:CD002003.
- GL Bakris et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.
- Nebivolol (Bystolic) for hypertension. Med Lett Drugs Ther 2008; 50:17.
- J Fongemie and E Felix-Getzik. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75:1349.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283:1967.
- P Smith et al. Nifedipine in pregnancy. BJOG 2000; 107:299.
- WF Peacock IV et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 2012; 30:981.
- SN Molvi et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012; 285:1553.
- MY Yacoob et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013; 62:375.
- C Lydakis et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.